Latest Conference Articles

November 7th 2017, 11:00pm

ESGO Congress

A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer.

November 7th 2017, 10:00pm

ESGO Congress

The final analysis of overall survival data from the phase III AGO-OVAR 12 trial of nintedanib plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naive advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib.

November 7th 2017, 8:50pm

ESGO Congress

Patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score experienced prolonged progression-free survival after undergoing a second cytoreductive surgery followed by platinum-based chemotherapy.

November 7th 2017, 7:53pm

ESGO Congress

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

November 7th 2017, 7:52pm

ESGO Congress

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

November 1st 2017, 11:51pm

IASLC World Conference on Lung Cancer

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

November 1st 2017, 11:44pm

IASLC World Conference on Lung Cancer

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

October 25th 2017, 12:09am

IASLC World Conference on Lung Cancer

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with lung cancer.

October 25th 2017, 12:07am

IASLC World Conference on Lung Cancer

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

October 22nd 2017, 12:54am

SMR Congress

The combination of adjuvant nivolumab and ipilimumab led to a 3-year relapse-free survival rate of 71% in patients with high-risk resected stage IIIC/IV melanoma.

October 21st 2017, 9:53pm

SMR Congress

A doubling in 3-year relapse-free survival rates remained consistent across patient subgroups treated with dabrafenib and trametinib, when compared with placebo, for patients with BRAF-mutant stage III melanoma.

October 21st 2017, 9:15pm

SMR Congress

Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.

October 21st 2017, 9:12pm

SMR Congress

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.

October 21st 2017, 7:26pm

SMR Congress

The combination of nivolumab and ipilimumab showed an intracranial response rate of 46% for asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

October 20th 2017, 8:05pm

SMR Congress

The combination of anti–PD-1/PD-L1 immunotherapy with BRAF plus MEK inhibitors is advancing rapidly following early promising phase results for patients with BRAF-mutant advanced melanoma.

October 20th 2017, 6:00pm

SMR Congress

Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.

October 20th 2017, 5:07pm

SMR Congress

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

October 20th 2017, 4:59pm

SMR Congress

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the Columbus trial for patients with melanoma.

October 20th 2017, 5:13am

SMR Congress

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.

October 20th 2017, 2:37am

SMR Congress

Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.